Trial of bivalirudin during angioplasty reports mixed results

Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints -- a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding -- as compared to patients receiving standard anticoagulation therapy, according to a new study.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1FHvxw7